United Therapeutics Corporation (NASDAQ:UTHR - Get Free Report) CEO Martine Rothblatt sold 9,500 shares of the company's stock in a transaction that occurred on Friday, April 24th. The shares were sold at an average price of $564.81, for a total transaction of $5,365,695.00. Following the completion of the transaction, the chief executive officer owned 40,513 shares in the company, valued at approximately $22,882,147.53. This represents a 19.00% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.
United Therapeutics Stock Down 0.0%
UTHR stock opened at $566.99 on Tuesday. The company has a 50 day moving average of $538.38 and a two-hundred day moving average of $495.47. The company has a market cap of $24.85 billion, a price-to-earnings ratio of 20.32, a PEG ratio of 1.61 and a beta of 0.75. United Therapeutics Corporation has a 12-month low of $272.12 and a 12-month high of $607.89.
United Therapeutics (NASDAQ:UTHR - Get Free Report) last posted its quarterly earnings results on Wednesday, February 25th. The biotechnology company reported $7.70 EPS for the quarter, beating the consensus estimate of $6.78 by $0.92. United Therapeutics had a net margin of 41.94% and a return on equity of 19.30%. The business had revenue of $790.20 million for the quarter, compared to analysts' expectations of $814.80 million. During the same period in the previous year, the company posted $6.19 EPS. United Therapeutics's revenue was up 7.4% on a year-over-year basis. On average, research analysts anticipate that United Therapeutics Corporation will post 27.97 EPS for the current year.
Institutional Investors Weigh In On United Therapeutics
A number of hedge funds have recently bought and sold shares of UTHR. Simplify Asset Management Inc. grew its position in shares of United Therapeutics by 43.7% in the first quarter. Simplify Asset Management Inc. now owns 34,251 shares of the biotechnology company's stock valued at $20,310,000 after purchasing an additional 10,412 shares during the last quarter. HB Wealth Management LLC boosted its stake in United Therapeutics by 16.0% during the 1st quarter. HB Wealth Management LLC now owns 2,327 shares of the biotechnology company's stock valued at $1,380,000 after purchasing an additional 321 shares during the period. PFG Investments LLC acquired a new stake in United Therapeutics in the 1st quarter valued at approximately $208,000. Fjarde AP Fonden Fourth Swedish National Pension Fund increased its position in United Therapeutics by 45.4% in the 1st quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund now owns 40,530 shares of the biotechnology company's stock worth $24,033,000 after buying an additional 12,650 shares during the period. Finally, Strs Ohio lifted its holdings in shares of United Therapeutics by 68.2% during the first quarter. Strs Ohio now owns 27,614 shares of the biotechnology company's stock worth $16,375,000 after buying an additional 11,198 shares during the last quarter. 94.08% of the stock is currently owned by institutional investors.
Analysts Set New Price Targets
Several brokerages recently commented on UTHR. Wells Fargo & Company boosted their price target on United Therapeutics from $486.00 to $575.00 and gave the company an "equal weight" rating in a research note on Tuesday, March 31st. Cantor Fitzgerald boosted their target price on shares of United Therapeutics from $525.00 to $625.00 and gave the stock an "overweight" rating in a research report on Thursday, March 12th. Bank of America increased their price target on shares of United Therapeutics from $569.00 to $626.00 and gave the stock a "neutral" rating in a research note on Tuesday, March 31st. TD Cowen lifted their price objective on shares of United Therapeutics from $575.00 to $660.00 and gave the company a "buy" rating in a research note on Monday, March 30th. Finally, Oppenheimer upped their price objective on shares of United Therapeutics from $575.00 to $600.00 and gave the stock an "outperform" rating in a report on Thursday, February 26th. Ten analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $601.50.
Get Our Latest Report on United Therapeutics
About United Therapeutics
(
Get Free Report)
United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company's primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
